ABSTRACT
INTRODUCTION
Diabetic nephropathy (DN) is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. It is due to longstanding diabetes mellitus (1) . The susceptibility to DN varies among T2DM, and its etiology is multi-factorial involving acquired and inherited risk factors . The former exemplified by poor glycemic control and hypertension , while the latter was highlighted by a genetic predisposition based on familial clustering of DN (4 & 5) . Plasma homocysteine (Hcy), a non-protein sulfur amino acid that is itself a risk factor for arteriosclerosis and atherothrombosis. It is biosynthesized from methionine by the removal of its terminal methyl group. Hcy can be recycled into methionine or converted into cysteine with the aid of methylenetetrahydrofolate (MTHF) and vitamins B 6 . Plasma tHcy level is a graded and independent risk factor for coronary and other forms of vascular disease. Mild hyperhomocysteinemia is an independent risk factor for several vasculopathies including atherosclerosis, acute myocardial infarction, cerebrovascular disease and carotid artery stenosis (6) . Methylene -tetrahydrofolate reductase (MTHFR) is an enzyme involved in the reduction of methylene tetrahydrofolate to methyl tetrahydrofolate which is a carbon donor in remethylation Hcy to methionine. MTHFR deficiency is associated with hyperhomocysteinemia, an independent risk factor for thrombotic disorders including arteriosclerosis and arterial thrombosis (6,7) . Two common mutations within MTHFR gene were reported; first is MTHFR-C677T (alanine to valine substitution at amino acid 226) and second MTHFR-A1298C, (glutamate to alanine at amino acid 429) which were reportedly linked with moderate hyperhomocysteinemia (8) . The aim of the current study was to evaluate the serum Hcy level in diabetic nephropathy in Egyptian type 2 DM patients. Its common genetic polymorphisms (MTHFR C677T and A1298C) were determined for 75 T2DM patients with DN, 55 T2DM patients without nephropathy and also 95 non-diabetic control subjects together with their correlation with changes in Hcy levels.
MATERIALS & METHODS
Fifty-five adult patients (36 males and 19 females; mean age 55.7 ± 11.5 years), who were diagnosed as DN by abnormal urinary protein concentration (albuminuria >30 g/24 hours), high serum creatinine levels above 1.3 mg/dl or low glomerular filtration rate (GFR) levels (below 90 ml/minute). Another group was 75 adult patients (47 males and 28 females; mean age 48.7 ± 12.3 years) and was diagnosed T2DM based on 1998 WHO diagnostic and classification criteria (WHO) from outpatient clinic Sohag Faculty of Medicine without renal impairment. None of the patients had ketoacidosis, and treatment for diabetes included diet and/or oral antidiabetic drugs and/or insulin to achieve glycemic control. The control group included 95 non-diabetic subjects (51 males and 44 females; mean age 55.6 ± 14.1 years) without known personal or family history of diabetes. The University of Sohag Ethics Committee approved the study and informed consent was obtained from all participants according to the study protocol.
For all subjects, complete history was recorded, which included age; gender; ethnic origin; age of onset, duration and first-degree family history of diabetes; dyslipidemia, ischemic heart disease and other medical illness; history of chronic complications of diabetes, treatment for diabetes including date of initiation and/or discontinuation of oral agents or insulin and history of other medication.
After 
Microalbumin assay:
It was done by competitive ELISA (ALPCO; Catalog Number: 24-MABHU-E01) in which enzyme labeled albumin competes with albumin in samples for limited antibody binding sites on the microplate. After incubation for a fixed time, separation of bound from free is achieved by simple decantation and plate washing. The enzyme activity on the plate is measured using an enzyme substrate and a chromogen. The absorbency of the color developed is read in an ELISA colorimetric reader at 450 nm. The measured absorbance is inversely proportional to the concentration of bound albumin in the microplate. The concentration of albumin in the urine is determined from a calibration curve. Glomerular filtration rate (GFR): GFR was calculated using the formula (urine volume x urine creatinine)/ (1440 x plasma creatinine)
(9)
. Lipid profile: Serum total cholesterol and triglyceride were determined by enzymatic colormetric methods. Also, HDL-cholesterol and LDL-cholesterol were measured using the cholesterol -esterase and cholesterol -oxidase enzymes (Randox © , England902).
Homocysteine assay:
Enzyme Immunoassay (EIA: Alpico cat. No. 66=HCYHU-E01) for the determination of total homocysteine (tHcy) in blood was done. Protein-bound tHcy is reduced to free tHcy by dithiothreitol (DDT) and enzymatically converted to Sadenosyl-L-homocysteine (SAH) by SAH-hydrolase prior to the immunoassay. Solid phase EIA is based on competition between SAH in the sample and immobilized SAH bound to the walls of the microtitre plate for binding sites on monoclonal anti-SAH antibody. After removal of unbound anti-SAH antibody, a second rabbit antimouse antibody labeled with horse radish peroxidase (HRP) is added. The peroxidase activity is measured spectrophotometrically at 450 nm.
MTHFR genotyping:
Total genomic DNA was isolated by the phenol chloroform method. MTHFR genotype analysis was performed by PCR-RFLP analysis using HinfI (10) and MboII digestion (Boehringer Mannheim, Germany) for C677T and A1298C detection, respectively. The selected primer sequences for C677T were: forward, 5`-TGA AGG AGA AGG TGT CTG GGG GA-3`, and reverse, 5`-AGG ACG GTG CGG TGA GAG TG-3`. The C677T mutation introduces a new HinfI restriction site which results in the digestion of the 198 bp amplicon into 175 and 23 bp fragments . MTHFR A1298C SNP was analyzed using similar conditions to the C677T using the following primer set: forward, 5`-CTT TGC GGA GCT GAA GGA CTA CTA C-3`, and reverse, 5`-CAC TTT GTG ACC ATT CCG GTT TG-3`. In wild-type (A1298A) 
RESULTS
The general characteristics of the studied population are shown in table 1. fig. 1-B) was detected in MTHFR-C677C wild type (198 bp), digested fragments (23 and 175 bp) were detected in homozygous MTHFR-T677T ( fig. 1-C) and digested and undigested fragments (23, 175 and 198 bp) were detected in heterozygous MTHFR-C677T ( fig. 1-D) . MTHFP-A1298C polymorphism: As figure 1, MTHFR-A1298A wild type (56, 31, 30, 28 and 18 bp) was detected as three bands ( fig. 1-E) , homozygous MTHFR-C1298C (84, 31, 30 and 18 bp) were detected as three bands ( fig. 1-F) and MTHFR-A1298C heterozygous mutation was detected as (84, 56, 31, 30, 28 and 18 bp) as four bands ( fig. 1-G) .
Fig.(1): (A) DNA ladder, (B) MTHFR-C677C wild type, (C) MTHFR-T677T homozygous mutation, (D) MTHFR-C677T heterozygous mutation, (E) MTHFR-A1298A wild type, (F) MTHFR-C1298C homozygous mutation and (G) MTHFR-A1298C heterozygous mutation.
Frequencies of MTHFR-C677T and MTHFR-A1298C genotypes in control, type 2 DM and diabetic nephropathy were tabulated below (table 2). . High concentrations of Hcy have been associated with an increased risk of coronary heart disease, deep vein thrombosis, pulmonary embolism, and stroke
(12)
. Intracellular Hcy is either converted to cysteine via the vitamin B6-dependent transsulfuration pathway or is remethylated to methionine via cobalamin and tetrahydrofolate (THF) as cofactors. In the current study, plasma mean tHcy level was not higher in uncomplicated diabetic patients than control subjects. However, there was a significant difference in the tHcy mean level between DN and control subjects. There are also a positive correlation between plasma tHcy and macrovascular complications (13,14) or microvascular complications (1,9) . However, the relationship between tHcy and diabetic microvascular complications seems stronger than the relationship between tHcy and diabetic macrovascular complications of diabetes. It has been reported that incipient and overt nephropathy is associated with elevations of plasma tHcy in patients with type 2 diabetes
(9)
. In line with the present study, Hofmann et al., (1) found elevated tHcy levels in diabetic patients with nephropathy, whereas Robillon et al., (15) found reduced tHcy levels in diabetic patients without overt nephropathy. Hyperhomocysteinemia may act to induce DN by inducing the expression of tissue factor (TF) which is an initiator of blood coagulation in vivo . As a result of that mutation, valine appears instead of alanine in the 226 amino acid of the polypeptide chain. The frequency of that mentioned genotype was investigated in Europe, the Middle East, China, Oceania, Mexico, the United States, and Canada (20-22) . The prevalence of the homozygous TT genotype was 10% to 12% in several areas in Europe (e.g. France and Hungary). However, there were also areas of a significantly lower frequency of the TT genotype (ie, Helsinki, Finland, the northern Netherlands, and Russia), with frequencies of 4%, 6%, and 7%, respectively (8,23) . On the other hand, in southern Europe, the frequencies observed were as high as 26% and 20% in Campania and Sicily, respectively. In recurrent study, genotype C (homozygous (CC) and heterozygous (CT) forms are 90.5% and higher than that T both homozygous (TT) and heterozygous (CT) forms which are 23.2% in control group. In diabetic nephropathy, genotype T forms (homozygous and heterozygous) are 76.4% which are higher than C forms (63.6%) and are parallel with microalbuminuria. This substitution leads to the synthesis of a thermolabile form of MTHFR (18) . Hence, in subjects presenting the 677TT genotype, there is reduced formation of methyl-THF, and therefore, the individual's ability to methylate tHcy to methionine is lowered, resulting in increased levels of plasma tHcy (24) . The C677T mutation found within the MTHFR catalytic domain, while the A1298C mutation found in exon7, is located within the enzyme regulatory domain. This was in agreement with previous studies in many ethnic groups including Chinese , and Japanese , which demonstrated that MTHFR gene may be an aggravating factor for DN in T2DM patients. Others failed to find such an association (6) , and some suggested that gender (24) and low folate levels (27) may determine to a large extent the pathogenic nature of the C677T mutation.
In addition to the MTHFR C677T polymorphism, there is another one in the same gene resulting in changed enzyme activity. That polymorphism is located in exon 7 of MTHFR at 1298 bp, outside the catalytic domain and on the AdoMet-regulatory domain of the enzyme
(5)
. The mutation is an A-to-C transversion, which changes glutamic acid into an alanine residue in position 429. The enzyme expressed in polymorphic homozygotes manifests in decreased activity of approximately 60% of control values (5). In the current study, neither homozygous (CC) nor heterozygous (AC) subjects have a parallel role in elevated plasma tHcy
.
Nevertheless, numerous studies have found association of that polymorphism with cardiovascular diseases (14) and psychiatric disorders such as depression, schizophrenia and bipolar disorder (28) .
In conclusion, we found a positive relationship between the MTHFRC677T
(not A1298C) mutation, hyperhomocysteinemia, and DN in type 2 DM.
Despite the polymorphisms mentioned above, resulting mainly in mild hyperhomocysteinemia, there are also such mutations in the MTHFR gene that can cause hyperhomocysteinemia because of MTHFR deficiency, such as 559 C-to-T transition (Arg184Ter)
